Promotion of colorectal cancer progression by immune-related lnc-SOX9–4 via suppression of YBX1 poly-ubiquitination and degradation

Abstract

BackgroundRecent research has highlighted the versatile functions of long non-coding RNAs (lncRNAs) in the onset and progression of various malignancies. Still, insufficient knowledge is available on how lnc-SOX9–4 functions in colorectal cancer (CRC) progression. MethodsBioinformatics analysis was used to identify a novel lncRNA (lnc-SOX9–4), and the expression pattern of the RNA in CRC was verified using qRT-PCR. Gene ontology (GO) term analysis and Gene set enrichment analysis (GSEA) were implemented for the identification of the related mechanisms and roles of lnc-SOX9–4. Immune infiltration analysis was conducted for assessment of how lnc-SOX9–4 is linked to tumor immune cell infiltration level. Both in vitro and in vivo phenotype analyses were conducted for scrutinizing how lnc-SOX9–4 impacts the proliferation and metastasis of CRC. RNA pulldown, mass spectrometry analysis, fluorescent in situ hybridization (FISH), western blotting, and RIP assay aided in verifying lnc-SOX9–4 mechanisms linked to CRC progression. ResultsAn upregulation of lnc-SOX9–4 was observed in the sample CRC cells and tissues. Elevated lnc-SOX9–4 levels showed a positive association with poor clinical prognosis. Lnc-SOX9–4 was closely correlated to several types of immune infiltrating cells. Functionally, the knockdown of lnc-SOX9–4 significantly inhibited CRC cell proliferation, migration, and invasion abilities. Mechanistically, YBX1 was identified as lnc-SOX9–4, specifically interacting protein in the nucleus. Lnc-SOX9–4 could stabilize YBX1 protein levels by inhibiting poly-ubiquitination and degradation of YBX1. Furthermore, phenotype rescue experiments reveal that lnc-SOX9–4 enhanced the CRC cellular potential to proliferate and metastasize by regulating YBX1 levels. ConclusionsLnc-SOX9–4 promoted CRC progression by suppressing cytoplasmic translocation and promoting protein levels of YBX1 can serve as novel treatment targets for diagnosing and treating CRC.